We have mentioned in our paper that the phaco technique used was direct phaco chop technique. However, we agree that cumulative dissipated energy could also have been additionally analyzed. Although we did match the grade of cataracts in the two groups, we have not analyzed the endothelial cell loss by cataract grade because the cataract subgroups were unequally distributed and our study did not had enough statistical power for analysis. These are aspects which could be looked at in further studies.
Sir,
We read with interest the article entitled, "Fungal keratitis: The Aravind experience" by Prajna et al. [1] First, in the compilation of the clinical articles published on this topic by the researcher from that institution, shown in the Fig. 1 included in the article by Prajna et al., an older study than those referred (a masked, randomized clinical trial of three concentrations of chlorhexidine compared with natamycin 5%, published in 1997) is missing from the list. In fact, that study showed that chlorhexidine might be superior to natamycin. Compared with the response to natamycin as the referent, the relative efficacy was 1.17 with chlorhexidine 0.05%, 1.43 with 0.1%, and reached 2.00 with 0.2%. The superiority of 0.2% chlorhexidine over natamycin was statistically significant (relative efficacy 2.20, P = 0.043) in patients not having had prior antimycotic medication. [2] Since the investigators did not mention chlorhexidine 0.2% in their recent review, we wonder if they had any posterior negative experience using this substance in fungal keratitis.
The recent studies Mycotic Ulcer Treatment Trial I (MUTT I) and MUTT II, performed also by researchers from Aravind Eye Hospital, showed that topical natamycin was superior to topical voriconazole. [3, 4] Since in the clinical trial from 1997, it was found that chlorhexidine 0.2% could be twice as effective as natamycin, would not it be worth conducting a new study with chlorhexidine and natamycin? Not only to probably corroborate the earlier findings from 1997 but also to evaluate a possible synergy between them? Furthermore, in the recently published results from the study MUTT II (both for all cases of keratomycosis and for Fusarium keratitis), the researchers from Aravind indicated that all patients received topical voriconazole, 1%, and that after the results of the MUTT II study became available, topical natamycin, 5%, was added for all patients. [4, 5] It would be interesting to know if they have found any kind of synergy between these two medications. In the current protocol of their hospital, do they use both topical medications concurrently?
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Reply to Comment on: Fungal keratitis: The Aravind Experience
Sir, We would like to thank the reviewers for their interest in our publication. [1] Investigators in our department along with our collaborators conducted a randomized trial comparing the various concentrations of topical chlorhexidine (0.05%, 0.1%, and 0.2%) with 5% natamycin for fungal keratitis at our institution in 1997 and concluded that, the nonsevere fungal ulcers with no prior antifungal treatment, when treated with 0.2% chlorhexidine had a favorable outcome at 5 days from the initiation of the treatment compared to 5% natamycin. [2] However, comparison of the long-term outcome of nonsevere fungal ulcers was not statistically significant among the four groups. There was no difference in the outcomes of severe fungal ulcers. The study was limited by small sample size with 8 ulcers in chlorhexidine 0.2% group compared to 16 ulcers in natamycin group. Chlorhexidine is a nonspecific antiseptic which is not commercially available in our region and has to be formulated under strict aseptic precautions. The shelf life of chlorhexidine is <2 weeks. Hence, in our clinical practice, we reserve chlorhexidine 0.2% for corneal ulcers caused by acanthamoeba and we do not use it in fungal keratitis.
Mycotic ulcer treatment trial 2 (MUTT 2) evaluated the efficacy of oral voriconazole as an adjunct to topical antifungals in severe fungal keratitis [3] and concluded that oral voriconazole does not give added benefit in such a scenario. In this trial, topical natamycin was added to topical voriconazole in both the arms after analyzing the results of MUTT 1, which concluded that topical voriconazole should not be used as a monotherapy. [4] This addition of topical natamycin happened after the enrollment of 39 patients of the total sample size of 240 patients. The less number of patients receiving only topical voriconazole precludes any meaningful comparison to establish the superiority of using both natamycin and voriconazole. However, in our clinical practice, we do add topical voriconazole to topical natamycin in large, recalcitrant, and deep ulcers.
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